Analysis of information sources in references of the Wikipedia article "วัคซีนโควิด-19 ของออกซฟอร์ด-แอสตร้าเซนเนก้า" in Thai language version.
{{cite web}}: CS1 maint: url-status (ลิงก์){{cite web}}: CS1 maint: url-status (ลิงก์){{cite web}}: CS1 maint: url-status (ลิงก์){{cite web}}: CS1 maint: url-status (ลิงก์){{cite web}}: CS1 maint: url-status (ลิงก์){{cite web}}: CS1 maint: url-status (ลิงก์){{cite web}}: CS1 maint: url-status (ลิงก์){{cite web}}: CS1 maint: url-status (ลิงก์){{cite web}}: CS1 maint: url-status (ลิงก์){{cite web}}: CS1 maint: url-status (ลิงก์){{cite web}}: CS1 maint: url-status (ลิงก์){{cite web}}: CS1 maint: url-status (ลิงก์)WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
{{cite journal}}: Cite journal ต้องการ |journal= (help){{cite web}}: CS1 maint: url-status (ลิงก์){{cite journal}}: Cite journal ต้องการ |journal= (help)WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.
It is known from the clinical trials that the more common side effects for both vaccines can occur at a rate of more than one in 10 doses (for example, local reactions or symptoms resembling transient flu-like symptoms)
{{cite journal}}: Cite journal ต้องการ |journal= (help){{cite news}}: CS1 maint: url-status (ลิงก์){{cite news}}: CS1 maint: url-status (ลิงก์)... แต่เราคาดการณ์ว่าจะสามารถจัดสรรวัคซีนให้กับประเทศไทยได้โดยเฉลี่ย 5-6 ล้านโดสต่อเดือน... เราได้พยายามเพิ่มประสิทธิภาพในกระบวนการผลิตให้ดียิ่งขึ้นกว่าเดิม และเรามั่นใจว่า จะสามารถส่งมอบวัคซีนได้มากขึ้นในอีกไม่กี่เดือนข้างหน้า...
WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.